CliffBio
biologic

Pertzye

pancrelipase

Loss of exclusivityOctober 2028projected — 12-year biologic exclusivity estimate
CompanyDigestive Care, Inc. →View the full company profile on CliffBio

Drug detail

Brand namePertzye
Active ingredientpancrelipase
Strength4,000USP UNITS; 14,375USP UNITS; 15,125USP UNITS
Dosage formCapsule, Delayed Release
RouteOral
ModalityBiologic
FDA approvalOctober 2016
Marketing statusRx

More from Digestive Care, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Pertzye patent cliff — loss of exclusivity October 2028 | CliffBio